Summary
Betaxolol has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Age-Related Macular Degeneration (AMD) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Age-Related Macular Degeneration (AMD). No registered clinical trial in this database tests Betaxolol specifically in Age-Related Macular Degeneration (AMD). The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study. The literature layer holds 2 publications for this pair: 2 clinical trial publications. Publication years run from 2003 to 2004. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
The RepurpOS disease-intelligence file for Age-Related Macular Degeneration ranks 450 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Dry AMD: slow progressive loss; wet AMD progresses rapidly without treatment (50% of untreated reach legal blindness within 2 years); no spontaneous remission of either form.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 24.0 (trials 0.0, literature 4.0, tier 15, approved bonus 5.0) |
| Registered trials | 0 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 2 (2 clinical trial publications) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | inhibitor |
| Data sources | DGIdb |
| Linked via biomarker / target | ADRA2C |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
No registered trial links Betaxolol to Age-Related Macular Degeneration (AMD) in the current OSMF trial extract.
Published literature
- Clinical trial publication [Serum lipid profile in non-exudative AMD patients treated with locally administrated beta-blockers]Gebka A, Iwaszkiewicz-Bilikiewicz B, Raczyńska K et al. · Klinika oczna · 2004 · PMID 15636216
- Clinical trial publication Randomized clinical trial of topical betaxolol for persistent macular edema after vitrectomy and epiretinal membrane removalKobayashi H, Kobayashi K, Okinami S · American journal of ophthalmology · 2003 · PMID 12888045
Mechanism and notes
Recorded mechanism or class: inhibitor.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ADRA2C. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Betaxolol approved for Age-Related Macular Degeneration (AMD)?
Betaxolol has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Age-Related Macular Degeneration (AMD) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Age-Related Macular Degeneration (AMD). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Betaxolol in clinical trials for Age-Related Macular Degeneration (AMD)?
No registered clinical trial in this database tests Betaxolol specifically in Age-Related Macular Degeneration (AMD). The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study.
What does the evidence show for Betaxolol in Age-Related Macular Degeneration (AMD)?
The record for Betaxolol in Age-Related Macular Degeneration (AMD) rests on 2 publications without a registered trial. This is a lead for hypothesis generation, not evidence of efficacy. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ADRA2C. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.